Medexus Pharmaceuticals Inc. (MDP.TO)
| Previous Close | 1.7700 |
| Open | 1.8100 |
| Bid | 1.7700 x N/A |
| Ask | 1.8000 x N/A |
| Day's Range | 1.7700 - 1.8400 |
| 52 Week Range | 1.1200 - 3.5300 |
| Volume | |
| Avg. Volume | 53,591 |
| Market Cap | 43.78M |
| Beta (5Y Monthly) | 1.85 |
| PE Ratio (TTM) | 4.47 |
| EPS (TTM) | 0.4000 |
| Earnings Date | Feb 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.21 |
NewsfileMedexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's commercialization rights to Metoject®, have elected not to appeal the trial court decision. Medexus and medac initiated the litigation in August 2020 in response to the "at-risk" launch of a generic ...
NewsfileMedexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024.Event: 2024 Bloom Burton & Co. Healthcare Investor ConferenceDate: April 16-17, 2024Location: Toronto, OntarioMedexus Presentation: Wednesday, April 17 at 1:30 PM Eastern timeKen d'Entremont, Medexus's Chief Executive
NewsfileFDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration (FDA) recently approved Medexus's supplemental Biologics License Application (sBLA) for IXINITY® [coagulation factor IX (recombinant)] for the on-dem
